Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling

Journal of Pathology

Volumn 222, Issue 2, 2010, Pages 180-190

  Hussain, Azhar R ^a   Uddin, Shahab ^a   Ahmed, Maqbool ^a   Bu, Rong ^a   Ahmed, Saeeda O ^a   Abubaker, Jehad ^a   Sultana, Mehar ^a   Ajarim, Dahish ^a   Al Dayel, Fouad ^a   Bavi, Prashant P ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

AKT; Apoptosis; DLBCL; XIAP

Indexed keywords

PROTEIN KINASE B; X LINKED INHIBITOR OF APOPTOSIS; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; CASPASE; CHROMONE DERIVATIVE; EMBELIN; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR MARKER; TUMOR PROTEIN; XIAP PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; AGED; CANCER STAGING; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CASPASES; CELL DIVISION; CHROMONES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MORPHOLINES; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77957961226     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2747     Document Type: Article

References (46)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
2. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6387-6393. (Pubitemid 46218851)
3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
4. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916-2923.
5. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
6. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-1143.
7. Abedini MR, Muller EJ, Bergeron R, et al. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2010;29:11-25.
8. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E (mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001;27:206-216.
9. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999;17:781-828.
10. Robertson JD, Gogvadze V, Zhivotovsky B, et al. Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem 2000;275:32438-32443.
11. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and-independent pathways in cisplatinresistant and-sensitive human ovarian cancer cell lines. Cancer Res 1999;59:3077-3083.
12. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell death proteases. Nature 1997;388:300-304.
13. Augello C, Caruso L, Maggioni M, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009;9:125.
14. Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81:824-831.
15. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999;13:239-252.
16. Liu Z, Sun C, Olejniczak ET, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000;408:1004-1008.
17. Riedl SJ, Renatus M, Schwarzenbacher R, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001;104:791-800.
18. Bilim V, Kasahara T, Hara N, et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistance TCC in vitro. Int J Cancer 2003;103:29-37.
19. Tamm I, Trepel M, Welsh K, et al. Peptides targeting caspase inhibitors. J Biol Chem 2003;278:14401-14405.
20. Smith PG, Wang F, Wilkinson KN, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005;105:308-316.
21. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
22. 2 in vascular smooth muscle cells: potential involvement in vascular disease. Int JMolMed 2003;11:229-234.
23. Eves EM, Xiong W, Bellacosa A, et al. Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. Mol Cell Biol 1998;18:2143-2152.
24. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186.
25. Uddin S, Hussain AR, Al-Hussein KA, et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-3108.
26. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405-5412.
27. Sonoda Y, Matsumoto Y, Funakoshi M, et al. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 2005;275:16309-16315.
28. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862-1868.
29. 6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther 2007;321:616-625.
30. Liu X, Shi Y, Giranda VL, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther 2006;5:494-501.
31. Gagnon V, Themsche C, Turner S, et al. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008;13:259-271.
32. Van Themsche C, Mathieu I, Parent S, et al. Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent upregulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J Biol Chem 2007;282:4794-4802.
33. Abubaker J, Bavi P, Al-Harbi S, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008;27:3539-3545. (Pubitemid 351793794)
34. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours. IARC Press: Lyon, 2001.
35. Bavi P, Jehan Z, Atizado V, et al. Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1708-1718. (Pubitemid 44497108)
36. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical cmethods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721.
37. Uddin S, Hussain AR, Ahmed M, et al. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B cell lymphoma. J Pathol 2008;216:483-494.
38. Bavi P, Abubaker J, Hussain A, et al. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008;39:885-894.
39. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cutpoint optimization. Clin Cancer Res 2004;10:7252-7259.
40. Hussain A, Al-Rasheed M, Manogaran PS, et al. Curcumin induced apoptosis in acute T cell leukemia. Apoptosis 2006;11:245-254.
41. Hussain AR, Al-Jomah NA, Siraj AK, et al. Sanguinarinedependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007;67:3888-3897.
42. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005;24:7022-7030.
43. Hussain AR, Ahmed M, Al-Jomah NA, et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008;7:3318-3329.
44. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-κB (NF-κB) signaling pathway leading to suppression of NF-κB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol 2007;71:209-219.
45. Nikolovska-Coleska Z, Xu L, Hu Z, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004;47:2430-2440.
46. Aird KM, Baras A, Wei J, et al. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 2008;7:38-47.